Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Limitations of this study include its descriptive, observational design, with no statistical comparisons of outcomes within or between treatment cohorts
every current supply is compounded or research-grade, and its human evidence base is older and mostly about pediatric growth-hormone deficiency
Licensed 503A compounding pharmacies can create single-use vial formulations without preservatives, though these require more frequent injection doses
FDA Approval and Indications PT-141 was approved by the FDA in June 2019 under the brand name Vyleesi specifically for the treatment of: Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women
US$ 26.06
US$ 24.76
US$ 25.88
US$ 26.17
US$ 29.86
US$ 21.81
US$ 28.13
US$ 28.33
US$ 28.45
US$ 20.19
US$ 29.20
